Jane Withnall

Title: Jane Withnall: Innovator in Pharmaceutical Chemistry

Introduction

Jane Withnall is a prominent inventor based in Loughborough, GB. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds and their applications in medicine. With a total of 2 patents, her work has garnered attention in the scientific community.

Latest Patents

Among her latest patents is a groundbreaking invention related to the crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline. This invention focuses on chemical processes useful in the manufacture of this compound, which is the active entity within AZD0530. It also includes the development of particular crystalline forms, such as a difumarate salt and a trihydrate, along with pharmaceutical compositions containing these forms. Another notable patent involves a pharmaceutically acceptable salt of N-[2-(diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide, which is intended for use as a medicament in treating respiratory diseases like asthma or COPD.

Career Highlights

Jane Withnall is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. Her work at AstraZeneca has allowed her to focus on innovative solutions in drug development and contribute to advancements in healthcare.

Collaborations

Throughout her career, Jane has collaborated with notable colleagues, including James Gair Ford and James Francis McCabe. These collaborations have further enhanced her research and development efforts in the pharmaceutical sector.

Conclusion

Jane Withnall's contributions to pharmaceutical chemistry and her innovative patents highlight her role as a key figure in the industry. Her work continues to impact the development of effective treatments for various medical conditions.